East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Leflunomide Tablets USP, 10 mg and 20 mg. Aurobindo Pharma’s Leflunomide Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Arava® Tablets marketed by Sanofi-aventis U.S. LLC.

Leflunomide Tablets are indicated for:

• The treatment of adults with active rheumatoid arthritis